Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females

Table 5

Reduction in abnormal cytology irrespective of HPV causation, colposcopy, and excisional treatments [57].

	Population	Vaccine efficacy (96.1% confidence intervals)
ASCUS	TVC-N	23% (17, 29)
LSIL	TVC-N	24% (14, 33)
HSIL	TVC-N	54% (5, 79)
Reduction in colposcopy exams	TVC-N	29% (22, 36)
Reduction in excisional procedures	TVC-N	70% (58, 79)

TVC-N means TVC naive: a TVC subset including women 15–25 years old who received ≥1 vaccine dose with normal cytology, seronegative for HPV-16/18 and DNA-negative for 14 oncogenic HPV types at baseline ((16, 18, 31. 33, 35, 39,45, 51, 52, 56, 58, 59, 66, and 68); case counting starting first day after first injection. Subjects were followed for an average of 39.5 months after first injection.
ASCUS means atypical squamous cells of undetermined significance irrespective of HPV type association.
LSIL means low-grade squamous intraepithelial lesion irrespective of HPV type association.
HSIL means high-grade squamous intraepithelial lesion irrespective of HPV type association.